证券代码：688085 证券简称：三友医疗 公告编号：2025-073 上海三友医疗器械股份有限公司 股东询价转让计划书 QM5 LIMITED（以下简称"出让方"）保证向上海三友医疗器械股份有限公 司（以下简称"公司"或"三友医疗"）提供的信息内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中信证券股份有限公司（以下简称"中信证券"）组织实施本次询 价转让。截至 2025 年 9 月 22 日，出让方所持首发前股份的数量、占总股本比例 情况如下： | 序号 | 股东名称 | 持股数量（股） | 持股占总股本比例 | | --- | --- | --- | --- | | 1 | QM5 LIMITED | 49,146,564 | 14.74% | 出让方声明，出让方所持股份已经解除限售，权属清晰。出让方不存在《上 市公司股东减持股份管理暂行办法》、《上海证券交易所上市公司自律监管指引 第 15 号— ...

中信证券股份有限公司 关于上海三友医疗器械股份有限公司股东 向特定机构投资者询价转让股份 相关资格的核查意见 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 1 | 企业名称 | QM5 | LIMITED | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 类型 | 外资企业 | | 成立日期 | | 2013 年 | 10 | 月 29 | 日 | | 注册地址 | | 香港皇后大道中 15 | 号置地广场告罗士打大厦 | 42 楼 | 4205-06 | 室 | | | | 主营业务 | 对外投资 | | | | | | | | 中信证券股份有限公司（以下简称"中信证券"）受上海三友医疗器械股份 有限公司（以下简称"三友医疗"）股东 QM5 LIMITED（以下简称"出让方"） 委托，组织实施本次三友医疗首发前股东向特定机构投资者询价转让（以下简称 "本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创 板上市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规 ...

证券代码：688085 证券简称：三友医疗 公告编号：2025-072 上海三友医疗器械股份有限公司 关于联营公司产品通过创新医疗器械特别审查程序 的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海三友医疗器械股份有限公司（以下简称"公司"）孵化并投资的联营公 司春风化雨（苏州）智能医疗科技有限公司（以下简称"春风化雨"）脊柱手术 机器人及其相关智能化产品于近日通过国家药品监督管理局医疗器械技术审评 中心创新医疗器械特别审查程序，并被命名为脊柱外科手术导航定位系统，现将 相关情况公告如下： 一、产品基本信息 申报产品名称：脊柱外科手术导航定位系统 申请人：春风化雨（苏州）智能医疗科技有限公司 产品管理类别：第三类 二、产品情况介绍 本次通过国家药品监督管理局医疗器械技术审评中心创新医疗器械特别审 查程序的产品为春风化雨自行研发制造的手术机器人，具有首创的多臂手术机器 人技术。产品的主要创新优势如下： 1、创新性地将传统的单臂手术机器人升级为三臂手术机器人。其中，头部 视觉臂专注于手术过程中的精准定位与实时 ...

格隆汇9月22日丨三友医疗(688085.SH)公布，拟参与三友医疗首发前股东询价转让（以下简称"本次询 价转让"）股东为QM5 LIMITED；出让方拟转让股份的总数为6,669,250股，占三友医疗总股本的比例为 2.00%；本次询价转让为非公开转让，不会通过集中竞价交易或大宗交易方式进行。受让方通过询价转 让受让的股份，在受让后6个月内不得转让。 ...

智通财经APP讯，三友医疗(688085.SH)发布股东询价转让计划书，拟参与本次询价转让股东为QM5 LIMITED，拟转让股份的总数为666.925万股，占公司总股本的比例为2%。 ...

Core Viewpoint - The approval of the spinal surgery robot and related intelligent products by the National Medical Products Administration marks a significant milestone for the company and its innovation strategy in the medical device sector [1][2]. Group 1: Product Development - The spinal surgery robot, named the spinal surgical navigation positioning system, integrates advanced technologies such as multi-arm robotic systems, lightweight medical-grade mechanical structures, electromagnetic navigation, and optical imaging [1]. - The new generation of surgical robots aims to enhance AI intelligence, enabling clinical doctors to perform surgeries more accurately and safely, with customizable solutions based on specific surgical needs [1]. Group 2: Market Impact - The approval of the product for the innovative channel is a key milestone in the company's innovation research and development system, contributing to its growth strategy [2]. - The company’s other subsidiary, Suzhou Yunhejing, has also developed a "surface porous polyether ether ketone interbody fusion device," which is expected to enter the innovative channel by April 2025, further enhancing the company's product offerings [2].

Core Viewpoint - Sanyou Medical (688085.SH) announced that its incubated and invested joint venture, Chuanfeng Huayu (Suzhou) Intelligent Medical Technology Co., Ltd., has received approval for its spinal surgery robot and related intelligent products through the National Medical Products Administration's special review procedure for innovative medical devices, marking a significant milestone in the company's innovation and R&D system for 2025 [1] Group 1 - The product has been named the Spinal Surgery Navigation and Positioning System, indicating its advanced technological capabilities [1] - This approval allows the product to enter an innovative channel, which will provide priority processing rights during the registration application, effectively shortening the product registration cycle and accelerating its market launch [1] - The successful market approval of this product will positively impact the promotion and usage of related products under the innovative channel, enhancing the company's business prospects [1] Group 2 - Previously, another subsidiary of the company, Suzhou Yunhejing New Material Technology Co., Ltd., developed a "Surface Porous Polyether Ether Ketone Interbody Fusion Device," which also entered the innovative channel in April 2025 [1] - The entry of both products into the innovative medical device special review procedure signifies the company's commitment to advancing its product offerings in the medical technology sector [1]

三友医疗公告，公司股东QM5 LIMITED拟参与首发前股东询价转让，转让股份总数为666.92万股，占 公司总股本的2.00%。此次转让价格下限不低于发送认购邀请书之日（2025年9月22日）前20个交易日 股票交易均价的70%。受让方为具备相应定价能力和风险承受能力的机构投资者，且在受让后6个月内 不得转让股份。 ...

Core Viewpoint - Sanyou Medical has shown a mixed performance in stock price and financial metrics, with a notable increase in revenue and net profit year-on-year, indicating potential growth in the medical device sector [1][2]. Financial Performance - As of June 30, 2025, Sanyou Medical achieved a revenue of 250 million yuan, representing a year-on-year growth of 17.77% [2]. - The net profit attributable to shareholders reached 36.60 million yuan, marking a significant year-on-year increase of 2083.64% [2]. - The company has distributed a total of 113 million yuan in dividends since its A-share listing, with 39.75 million yuan distributed over the past three years [3]. Stock Performance - On September 22, 2023, Sanyou Medical's stock price increased by 2.15%, reaching 19.99 yuan per share, with a total market capitalization of 6.666 billion yuan [1]. - Year-to-date, the stock price has risen by 13.23%, while it has seen a slight decline of 0.05% over the last five trading days and a drop of 11.00% over the last 20 days [1]. - The stock has appreciated by 24.77% over the past 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 12.61% to 7,108, while the average number of circulating shares per person decreased by 11.20% to 34,954 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease of 1.5154 million shares held by Rongtong Health Industry Flexible Allocation Mixed A/B and an increase of 0.1646 million shares held by Southern Medicine Health Flexible Allocation Mixed A [3]. Business Overview - Sanyou Medical, established on April 19, 2005, and listed on April 9, 2020, specializes in the research, production, and sales of medical orthopedic implants and ultrasonic power devices and consumables [1]. - The company's main revenue sources include spinal implant consumables (63.80%), active devices and supporting accessories (31.51%), trauma implant consumables (3.53%), and others (1.16%) [1]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device and consumables sector [1].

Core Insights - The export value of China's medical devices reached $24.1 billion in the first half of 2025, showing a year-on-year growth of 5.0% [1] - The revenue and net profit growth rates for Sci-Tech Innovation Board medical device companies were 9% and 3% respectively, with significant quarter-on-quarter increases in Q2 [1] - Nearly 30% of Sci-Tech Innovation Board medical device companies have over 30% of their business from overseas markets, indicating a trend towards internationalization [1] Group 1: Industry Growth and Internationalization - Sci-Tech Innovation Board medical device companies are focusing on high-value consumables and medical equipment, supported by capital market resources to build global marketing networks [2] - The industry is characterized by a strong emphasis on innovation, international expansion, and mergers and acquisitions, with approximately 18,000 invention patents held by these companies [2] - Leading companies like United Imaging and Mindray have made significant advancements in global markets, with United Imaging's overseas revenue increasing from less than 10% at the time of listing to nearly 20% in the first half of 2025 [3] Group 2: Mergers and Acquisitions - The medical device industry is seeing deep integration through mergers and acquisitions, with companies like Sanyou Medical successfully acquiring international firms to enhance their product lines and market reach [4] - Sanyou Medical's acquisition of the French company Implanet has significantly boosted its overseas revenue, with a reported 41.10% year-on-year growth in Q2 2025 [4] - The trend of mergers and acquisitions is supported by national policies aimed at fostering high-quality development in the medical device sector [6] Group 3: Performance of Key Players - Huatai Medical, a leader in electrophysiology and vascular intervention consumables, has seen increased market penetration and product coverage following the introduction of Mindray Medical as a major shareholder [5] - Companies like Sanyou Medical, Weigao Orthopedics, and Chuangli Medical reported net profit growth rates exceeding 40%, while micro-electrophysiology and Bairen Medical saw growth rates over 90% [5] - Nanwei Medical's acquisition of a Spanish company has further deepened its penetration into the European market, with overseas revenue increasing by 45% to 898 million yuan in the first half of 2025 [5]